« Back to Record
Citation APA

Cornely, O. A., Meyer, R. R., Hammond, S. S., Mullane, K. K., Ostermann, H., Ullmann, A., Zimmerli, S., Van Iersel, M. M., Hepler, D. D., Waskin, H., Kartsonis, N., Robertson, M., Maertens, J., Haider, S., Grigg, A., Geddes, M., Aoun, M., Heinz, W. W., Raad, I. I., & Schanz, U. (2017). Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. Journal of antimicrobial chemotherapy, 72(12), 3501. doi:10.1093/jac/dkx263


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/268503

Cornely, O. A., Meyer, R. R., Hammond, S. S., Mullane, K. K., Ostermann, H., Ullmann, A., Zimmerli, S., Van Iersel, M. M., Hepler, D. D., Waskin, H., Kartsonis, N., Robertson, M., Maertens, J., Haider, S., Grigg, A., Geddes, M., Aoun, M., Heinz, W. W., Raad, I. I., & Schanz, U. (2017). Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. Journal of antimicrobial chemotherapy, 72(12), 3501. doi:10.1093/jac/dkx263